載入...
Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
Glioblastomas are characterized by amplification of EGFR. Approximately half of tumors with EGFR over-expression also express a constitutively active ligand independent EGFR variant III (EGFRvIII). While current treatments emphasize surgery followed by radiation and chemotherapy with Temozolomide (T...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5482605/ https://ncbi.nlm.nih.gov/pubmed/28410193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16767 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|